SCHEMBL3613221

SCHEMBL3613221

CCCCCC(NC(CCCCC)N1C(=O)C2CCCCC2C1=O)N1C(=O)C2CCCCC2C1=O

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CCR2 P41597 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
MAPK1 P28482 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MMP1 P03956 6/20 0.33
MMP3 P08254 6/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
GBA1 P04062 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1053481 0.78 KMT2A (0.36) KMT2ASMN1; SMN2CCR2ALDH1A1MEN1
SCHEMBL28116056 0.74 KMT2A (0.34) KMT2ASMN1; SMN2ALDH1A1MEN1MAPK1
SCHEMBL3621520 0.71 MGLL (0.44) KMT2ASMN1; SMN2ALDH1A1MEN1
SCHEMBL9157549 0.71 CYP1A2 (0.43) KMT2ASMN1; SMN2ALDH1A1MEN1MAPK1
SCHEMBL28409054 0.70 ALDH1A1 (0.34) KMT2ASMN1; SMN2ALDH1A1TDP1
SCHEMBL11845960 0.69 CNR2 (0.46) SMN1; SMN2ALDH1A1
SCHEMBL21846702 0.67 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1
SCHEMBL23422437 0.66 MEN1 (0.30) KMT2AALDH1A1MEN1MAPK1TDP1
SCHEMBL28890261 0.66 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1
SCHEMBL11628581 0.66 PDE4A (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032115-B1 COMPOSITIONS BASED ON HYPERBRANCHED CONDENSATION POLYMERS AND NOVEL HYPERBRANCHED CONDENSATION POLYMERS DSM IP ASSETS BV (NL) 2021-07-21 EP disclosed
EP-1991604-B1 NOVEL HETEROCYCLIC SUBSTITUTED CONDENSATION POLYMERS DSM IP ASSETS BV (NL) 2018-03-28 EP disclosed
US-8951509-B2 Heterocyclic substituted condensation polymers DSM IP ASSETS B.V. (NL) 2015-02-10 US disclosed
US-8394500-B2 Compositions based on hyperbranched condensation polymers and novel hyperbranched condensation polymers DSM IP ASSETS B.V. (NL) 2013-03-12 US disclosed
US-20100069601-A1 COMPOSITIONS BASED ON HYPERBRANCHED CONDENSATION POLYMERS AND NOVEL HYPERBRANCHED CONDENSATION POLYMERS DSM IP ASSETS B.V. (NL) 2010-03-18 US disclosed
US-20090068124-A1 NOVEL HETEROCYCLIC SUBSTITUTED CONDENSATION POLYMERS DSM IP ASSETS B.V. (NL) 2009-03-12 US disclosed
EP-2032115-A2 COMPOSITIONS BASED ON HYPERBRANCHED CONDENSATION POLYMERS AND NOVEL HYPERBRANCHED CONDENSATION POLYMERS DSMIP Assets B.V. (NL) 2009-03-11 EP disclosed
EP-1991604-A1 NOVEL HETEROCYCLIC SUBSTITUTED CONDENSATION POLYMERS DSMIP Assets B.V. (NL) 2008-11-19 EP disclosed
WO-2007144189-A2 COMPOSITIONS BASED ON HYPERBRANCHED CONDENSATION POLYMERS AND NOVEL HYPERBRANCHED CONDENSATION POLYMERS DSM IP ASSETS B.V. (NL) 2007-12-21 WO disclosed
WO-2007098889-A1 NOVEL HETEROCYCLIC SUBSTITUTED CONDENSATION POLYMERS DSM IP ASSETS B.V. (NL) 2007-09-07 WO disclosed
US-6730771-B2 THERMOPLASTIC, THERMOSETTING RESINS DSM N.V. (NL) 2004-05-04 US disclosed
EP-1171510-B1 CONDENSATION POLYMER CONTAINING DIALKYLAMIDE ENDGROUPS, PROCESS FOR PRODUCING SAID CONDENSATION POLYMERS AND APPLICATIONS THEREOF DSM IP ASSETS BV (NL) 2003-11-05 EP disclosed
US-6541110-B2 Endcapped polyamideester copolymers; compatible blend with another polymer DSM N.V. (NL) 2003-04-01 US disclosed
US-20020137880-A1 Condensation polymer containing dialkylamide endgroups, process for producing said condensation polymers and applications thereof DSM IP ASSETS B.V. (NL) 2002-09-26 US disclosed
US-20020019509-A1 Condensation polymer containing dialkylamide endgroups, process for producing said condensation polymers and applications thereof DSM N.V. (NL) 2002-02-14 US disclosed
EP-1038902-A1 Condensation polymers containing dialkylamide endgroups, process for their production and applications thereof DSM N.V. (NL) 2000-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090068124-A1 NOVEL HETEROCYCLIC SUBSTITUTED CONDENSATION POLYMERS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ACMSD, C9 KMT2A 468/4885SMN1; SMN2 1701/4885CCR2 3184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.